Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Nam cursus. Morbi ut mi. Nullam enim leo, egestas id, condimentum at, laoreet mattis, massa. Sed eleifend nonummy diam. Praesent mauris ante, elementum et, bibendum at, posuere sit amet, nibh. Duis tincidunt lectus quis dui viverra vestibulum. Suspendisse vulputate aliquam dui.Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim sit
Hyper Team
Dr. Zaven Khachaturian is the President of the Campaign to Prevent Alzheimer Disease (PAD2020.org). He is the former Director, Office of Alzheimer’s Disease at the National Institutes of Health (NIH), which was responsible for coordinating all Alzheimer’s disease related activities NIH-wide. He also serves as the Associate Director, Neuroscience & Neuropsychology of Aging Program at the National Institution on Aging NIA / NIH. He is widely recognized as the Chief Architect of NIH-funded programs of research on brain aging and dementia-Alzheimer syndrome.
Professor of Old Age Psychiatry at University College London, and Mental Health Lead of the University College London Hospitals’ Biomedical Research Centre. He and his colleagues investigate ways in which mental health symptoms in older people can be treated most effectively and safely through development of new psychological therapy approaches, optimizing the use of existing medications and of novel and repurposed agents. Their trials have shown the cognitive, functional, and independent living benefits of continuing dementia drugs until the late stages of Alzheimer’s disease.
Chairman
Dr. George Perry, former Dean of the College of Sciences, Semmes Distinguished University Chair in Neurobiology, Professor of Biology and Chemistry at the University of Texas at San Antonio. Dr. Perry is recognized in the field of Alzheimer’s disease research particularly for his work on oxidative stress. His research is primarily focused on the mechanisms and pathophysiological consequences of the cytopathology of Alzheimer disease. Dr. Perry is the current and founding editor-in-chief for the Journal of Alzheimer’s Disease, an international multidisciplinary journal that specializes in Alzheimer’s disease.
President & Chief Scientific Officer
Dr. Alkon has served as President and Chief Scientific Officer of Synaptogenix since September 2016 and the Founding Chief Scientific Officer since 2012 . A leader in the field, Dr. Alkon comes to Synaptogenix after 30 years directing programs on the molecular basis of associative memory at the National Neurologic Institute of NIH, and another 15 years as the Founding Scientific Director of the Blanchette Rockefeller. Neuroscience Institute where he and his team developed neurorestorative therapeutics for degenerative disorders of the central nervous system. He also served as the Toyota Chair of Neurodegenerative Diseases and Professor of Neurology at West Virginia University and Research Professor of Biophysics at Johns Hopkins University before joining Synaptogenix.
An internationally recognized pioneer in research on brain-based neural networks, the molecular basis of memory, and degenerative brain disorders, he has authored hundreds of scientific articles as well as several books, including Memory Traces in the Brain by Cambridge University Press, and the popular book Memory’s Voice by Harper Collins.
Dr. Alkon received his B.A. from the University of Pennsylvania, and his M.D. at Cornell University, after which he interned at the Mt Sinai Hospital in New York.
Chief Executive Officer
Alan Tuchman, MD, MBA (FAAN) has been with Synaptogenix since 2018, starting as Chief Medical Officer and becoming CEO in 2020. He is a Clinical Professor of Neurology at New York Medical College and the author of over 30 scientific papers and book chapters. He is currently in the private practice of Neurology in Manhattan. He served as Senior Vice President and Chief Medical Officer of Oncolytics Biotech Inc. from 2012-2017 and consults to a number of biotechnology and investment firms. He was as a partner of Xmark Opportunity Partners from 2002 – 2007 and as Executive Chairman of Neurophysics, Inc. from 2003 – 2008. He was the President of the Epilepsy Society of Southern New York from 1992 -1996 as well as Vice Dean for Clinical Affairs at New York Medical College from 1995-1997.
Dr. Tuchman received his MD degree from the University of Cincinnati, College of Medicine, and completed his Neurology Residency at the Mt Sinai School of Medicine. Dr. Tuchman received his MBA from Columbia University.
General Counsel and Chief Operating Officer
Dr. Ciraolo was most recently at Ovid Therapeutics, where he served as senior vice president, chief intellectual property counsel. Prior to joining Ovid, he was an executive director at Forest Laboratories where he held positions of increasing levels of responsibility. He has been involved with the development of numerous pharmaceutical products and transactional matters, including mergers, acquisitions and licensing opportunities. Dr. Ciraolo began his legal career as an associate at Baker Botts LLP in New York City, received a Ph.D. in chemistry from Stony Brook University and a J.D. from St. John’s University School of Law.
Chief Financial Officer
Mr. Weinstein joined the Company in June 2013 as its acting Chief Financial Officer. He has extensive accounting and finance experience, spanning more than 30 years, as a public accountant, investment banker, healthcare private equity fund principal and chief financial officer.
Mr. Weinstein served as an independent consultant for several healthcare companies in the pharmaceutical and biotechnology industries. Prior to joining Neurotrope, he was CFO at Green Energy Management Services Holdings, Inc., a publicly-traded energy consulting company, as well as CFO at Xcorporeal, Inc., a publicly-traded, development-stage medical device company which was sold to Fresenius Medical USA, the largest provider of dialysis equipment and services worldwide.
Mr. Weinstein received his MBA degree in finance and international business from the University of Chicago Graduate School of Business, is a Certified Public Accountant (inactive), and received his BS degree in accounting from the State University of New York at Albany.
Executive Director, Clinical Ops
Ms. Grenier has more than 25 years of experience in the pharmaceutical industry, with management responsibility for clinical trials in oncology, cardiovascular, central nervous system and genetic disease indications. Ms. Grenier participated in globalization of clinical development processes for a prominent pharmaceutical company to achieve uniform research standards across all global subsidiaries, with sensitivity to cultural and organizational differences. Ms. Grenier has provided management and leadership of multiple functional areas for integrated, comprehensive project oversight for US and international research programs.
Ms. Grenier attended the University of Maryland.
VP, Regulatory Affairs
Mr. Crockford has more than 30 years of professional experience in the biotechnology and pharmaceutical industries. Mr. Crockford led the development and obtained marketing approval of 18 drug products, 17 immunodiagnostic tests, and an intraoperative medical device. He co-founded and presided over one of the first publicly-held companies in the field of genetic engineering, pioneering the development and commercial application of monoclonal antibodies. Mr. Crockford has organized, presented and led discussions in many face-to-face meetings and teleconferences with a variety of Divisions and Centers (CBER, CDER and CDRH) at FDA. He provided the regulatory strategy and direction and led the clinical development of a regenerative peptide for the treatment of patients with certain ailments including neurodegenerative diseases.
Mr. Crockford is the author of a number of articles and sole inventor/co-inventor of approximately twenty patents and applications disclosing compositions, methods of drug use and delivery. He earned a Bachelor of Arts degree in biology from Boston University’s College of Arts and Sciences and completed seminars in clinical chemistry, sponsored by Princeton University/Princeton Hospital, and reproductive medicine at Wayne State’s Mott Center for Human Growth and Development and UCLA Medical School.
Chief Executive Officer
Appointed CEO of Neurotrope BioScience in February 2018, Dr. Ryan is an experienced executive with over 20 years of experience in drug development. Prior to joining Neurotrope, he served as CEO of Orthobond, a private company focused on creating proprietary surface modifications to enhance the function of medical devices or pharmaceuticals. Prior still, Dr. Ryan was VP and General Counsel at Cold Spring Harbor Laboratory, a preeminent non-profit institution focused in neuroscience, bioinformatics, cancer, genomics and plant biology. From 2004 until the acquisition by Actavis plc in 2014, Dr. Ryan was SVP Chief Intellectual Property Counsel for Forest Laboratories, a specialty pharmaceutical company in New York. At Forest Laboratories, Dr. Ryan led hundreds of due diligence teams, managed all aspects of patent and trademark litigations, developed cross-functional teams to establish a global strategy for hundreds of products. Two of the company’s most significant drugs were Lexapro (for major depressive disorders) and Namenda (for moderate to severe Alzheimer’s Disease). He began his career in biotechnology with The Collaborative Group, Ltd., a bioscience company providing development, research and manufacturing services to the pharmaceutical and skin care industries.
Dr. Ryan earned his Ph.D. from Stony Brook University, his J.D. from Western New England University, and his B.A. from The College of Wooster.